MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: An enzyme important for cancer's ability to spread

Back to cancer blog Blogs list Cancer blog  


Subscribe To Cancer Blog RSS Feed  RSS content feed What is RSS feed?

An enzyme important for cancer's ability to spread




In collaboration with the National Cancer Centre, Singapore, Van Andel Research Institute (VARI) scientists have identified an enzyme that could help diagnose and treat cholangiocarcinoma, a form of liver cancer that strikes up to 3,000 new patients each year in the United States.

Cholangiocarcinoma is the second most common type of cancer that affects the hepatobiliary system, which includes the liver, gall bladder, and bile ducts. The disease is most usually diagnosed in patients in their 60's and 70's, and prognosis is generally poor with a 5-year survival rate of less than 5%. The only current curative therapy of the disease is surgery to remove all tumor tissue, but most patients' cancer is too advanced upon diagnosis to operate.



An enzyme important for cancer's ability to spread

Southeast Asia is especially affected by cholangiocarcinoma, but occurence rate of the disease is rising in the United States, United Kingdom, and Australia.

"An advance in the diagnosis and therapy of this disease could have a profound impact," said Professor Khee Chee Soo, Director of the National Cancer Centre, Singapore. "Cholangiocarcinoma is particularly prevalent in Southeast Asia where, because of chronic infections by liver flukes and other factors, it kills thousands each year".

Cholangiocarcinoma and hepatocellularcarcinoma (HCC) are the two main forms of cancerous liver cancer and require different therapys. Scientists observed that the enzyme p38delta mitogen-activated protein kinase (MAPK13) is found in higher levels in cholangiocarcinomas than in HCC or normal tissue, and that it plays a role in the ability of tumor cells to move and invade normal tissue.

MAPK13 could be used as a complement to current biomarkers in diagnosing cholangiocarcinoma and distinguishing it from HCC, and it could serve as a drug target to help treat cholangiocarcinoma.

"Cholangiocarcinomas are notoriously challenging to diagnose and treat," said VARI Distinguished Scientific Investigator Bin Tean Teh, M.D., Ph.D., whose laboratory published its findings in the May 15 issue of the International Journal of Cancer. "Discoveries that lead to earlier detection and diagnosis will improve the long-term survival rate of patients".

Tissues used in the study were obtained from the National Cancer Centre, Singapore, and the Singapore General Hospital.


Posted by: Janet    Source




Did you know?
In collaboration with the National Cancer Centre, Singapore, Van Andel Research Institute (VARI) scientists have identified an enzyme that could help diagnose and treat cholangiocarcinoma, a form of liver cancer that strikes up to 3,000 new patients each year in the United States.

Medicineworld.org: An enzyme important for cancer's ability to spread

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.